CrystecPharma Awarded Prestigious Newton Fund Grant

May 22, 2017

CrystecPharma awarded prestigious Newton Fund grant to tackle the increasing burden of COPD in China through the development of novel inhalable treatments

CrystecPharma are delighted to announce that we have been awarded a highly prestigious and competitive grant from the Newton Fund to tackle the increasing burden of chronic obstructive pulmonary disease (COPD) in China. We will be working collaboratively with Dr Omar Usmani at Imperial College, Brompton Hospital, an international authority on aerosol science. We will also be working with two partners based in China: Professor Jiwen Zhang, a senior scientist at the Shanghai Institute of Materia Medica (SIMM) and pharmaceutical company Fudan Zhangjiang. Crystec is a UK- and China-based pharmaceutical research company focused on developing high-performing crystalline and composite particles. SIMM is the oldest comprehensive research institution for drug discovery and development in China and is recognized worldwide for its outstanding achievements and distinguished research team. Fudan Zhangjiang is a biopharmaceutical Company which is principally engaged in research, development, manufacture and distribution of innovative biopharmaceutical products. The project aims to implement a two-phase strategy to address the challenge of COPD. Firstly, by introducing an innovative supercritical fluid (SCF) technology to China, enabling respiratory products to be more easily developed for use in widely available devices and establishing a product evaluation platform that matches the best in the world. Secondly, to demonstrate the vitality of this technology and platform by introducing a novel COPD therapy which reduces airway inflammation and improves quality of life. To find out more about Crystec, visit CrystecPharma.com

To keep up to date with the latest news from Crystec, please follow us on LinkedIn.